Nuance Medical announced the successful acquisition of Biocorneum, a silicone gel scar treatment brand, previously owned by Sientra. Effective immediately, Biocorneum will become part of the Biodermis portfolio, Nuance Medical’s brand specializing in silicone scar management products. This strategic move enhances Biodermis’ commitment to providing top-tier skin care solutions to healthcare professionals.
With the addition of Biocorneum to Biodermis’ extensive line of scar management solutions, it ensures that the acclaimed properties of Biocorneum will continue under a brand that profoundly understands the needs and expectations of healthcare professionals and their patients. “Bringing Biocorneum into the Biodermis family marks a significant step in our journey to lead with innovative and impactful treatments in scar management," says Mark Steele, president of Nuance Medical. "This acquisition integrates Biocorneum’s strong presence in the professional healthcare sector with Biodermis’ comprehensive range of silicone scar management products. We are excited about the combined capabilities this brings and the enhanced benefits it offers to our healthcare partners and their patients.”